Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, gives an update on the Cell and Gene Therapy Catapult (CGTC) and it’s ongoing work in supporting the advanced therapies industry in 2021. With over 400 employees working across five different sites, the CGTC continues to grow rapidly in response to an increasing demand in the industry for new technologies. The introduction of the CGTC’s Braintree facility offers the capacity for the large-scale manufacture of vaccines for COVID-19, as well as other cell and gene therapies in the future. The CGTC also aims to capitalize upon stem cell research and development and contract research organization (CRO) capabilities in Edinburgh going forward. This interview took place at the Advanced Therapies Congress & Expo 2021.